Recently, an exon 2 p.G12C Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutation was introduced in the arena of positive predictive biomarkers to be tested for treatment selection in patients with metastatic non‐small cell lung cancer (NSCLC).1 The gene discussed is KRAS; the disease is lung cancer.